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Abstract
Background: Virus-binding activity is one of the important functions of fibronectin (FN). It has
been reported that a high concentration of FN in blood improves the transmission frequency of
hepatitis viruses. Therefore, to investigate a protease that hydrolyzes FN rapidly is useful to
decrease the FN concentration in blood and HBV infection. So far, however, no specific protease
digesting FN in serum has been reported.
Methods: We employed a purified earthworm protease to digest serum proteins. The rapidly
cleaved protein (FN) was identified by MALDI-TOF MS and western blotting. The cleavage sites
were determined by N-terminus amino acid residues sequencing. The protease was orally
administrated to rats to investigate whether serum FN in vivo became decreased. The serum FN
was determined by western blotting and ELISA. In cytological studies, the protease was added to
the medium in the culture of HepG2.2.15 cells and then HBsAg and HBeAg were determined by
ELISA.
Results:  The protease purified from earthworm Eisenia fetida was found to function as a
fibronectinase (FNase). The cleavage sites on FN by the FNase were at R and K, exhibiting a trypsin
alkaline serine-like function. The earthworm fibronectinase (EFNase) cleaved FN at four sites, R259,
R1005, K1557 and R2039, among which the digested fragments at R259, K1557 and R2039 were related to
the virus-binding activity as reported. The serum FN was significantly decreased when the
earthworm fibronectinase was orally administrated to rats. The ELISA results showed that the
secretion of HBeAg from HepG2.2.15 cells was significantly inhibited in the presence of the FNase.
Conclusion: The earthworm fibronectinase (EFNase) cleaves FN much faster than the other
proteins in serum, showing a potential to inhibit HBV infection through its suppressing the level of
HBeAg. This suggests that EFNase is probably used as one of the candidates for the therapeutic
agents to treat hepatitis virus infection.
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Background
Fibronectin (FN) is a glycoprotein composed of two
nearly identical ~250 kDa subunits linked covalently near
their C termini by a pair of disulfide bonds [1]. Each sub-
unit is a mosaic of a series of repeating modules: 12 Type
I, 2 Type II, 15 to 17 (depending on splicing) Type III
modules, and a variable (V) sequence that is not homolo-
gous to other parts of FN. The 2 Type III modules called
extradomain A (EDA) and extradomain B (EDB) are sub-
ject to alternative splicing [2]. On the basis of its solubil-
ity, FN is subdivided into two forms: soluble plasma FN
and less-soluble cellular FN [1]. Plasma FN that is synthe-
sized in hepatocytes contains neither EDA nor EDB
whereas cellular FN (synthesized locally in tissues) con-
tains variable amounts of either or both EDA and EDB. In
plasma FN dimers, only one of the subunits contains the
V region, whereas almost all cellular FN subunits contain
this region [2]. Plasma FN is an abundant soluble constit-
uent in plasma with a concentration about 300 μg/ml [1];
and cellular FN is an extracellular matrix that provides the
architectural scaffolding in tissues [3].
FN is a multifunctional molecule involving many physio-
logical and pathological processes such as infections with
different viruses [4,5], cellular adhesion, embryogenesis,
tissue damage and repair [6,7], atherosclerosis, myocar-
dial infarction [2,8] and tumor therapy [9]. Studies have
demonstrated that FN is involved in the virus infection,
including rabies virus [10], human immunodeficiency
virus (HIV) [11], cytomegalovirus [12], Rous sarcoma
virus (RSV) [13] and infectious hematopoietic necrosis
virus [4]. Recently, the interaction of hepatitis B virus
(HBV) with FN has been investigated by several laborato-
ries and their results have clarified that FN is related to
HBV infection [14-18].
HBV infection is a worldwide public health problem,
especially in the eastern countries. Globally, more than
350 million people are infected by HBV and 10~25% of
them die of either liver cirrhosis or hepatocellular carci-
noma [19]. Preventing the evolvement from transient
HBV infection into chronic HBV, liver cirrhosis and hepa-
tocellular carcinoma, human beings are encountering tre-
mendous challenge. There are several therapeutic agents
including interferon-α (IFN-α), peglyated IFN (PEG-IFN)
and four oral nucleotide analogues (lamivudine, adefovir,
entecavir and tonofovir) currently approved for the treat-
ment of chronic HBV [20]. But there are no proteases as
drugs in the therapeutic agents.
Previous studies have shown that FN is involved in HBV
infection, liver cirrhosis and hepatocellular carcinoma.
Budkowska and colleagues [14] have found that FN of
human liver sinusoids is able to bind to HBV via the pre-
s2 domain. This in vivo interaction of HBV with liver FN
may play a role in the initial steps of virus's entry into the
target cells, subsequently mediating by specific hepatocyte
receptors. FN expression increases markedly in sinusoidal
endothelial cells, and the matrixes deposit by these cells
stimulate the conversion of liver lipocytes to myofibrob-
lasts in rat hepatic fibrosis model. Matsui et al. [15]
reported that cellular FN participates in the hepatic fibro-
genesis and the hepatocellular carcinoma. In 2006, Wang
and colleagues [16] used an antisense oligonucleotide
(ASODN), fibronectin antibody, and a small molecular
compound to treat HepG2.2.15 cell line, targeting to FN.
Their results showed that a decrease in the concentration
of FN has an anti-HBV activity in HepG2.2.15 cells.
Earthworms have long been used as materials to make
drug for antipyretic and diuretic purposes in Chinese tra-
ditional medicine. Furthermore, some of earthworm pro-
teases have been prepared into enteric-coated capsules for
clinical use in China for more than 10 years [21,22].
Nakajima and co-workers [23] characterized six isozymes
of serine proteases with fibrinolytic activity from the
earthworm (E. fetida and L. rubellus). On the basis of their
cleavage specificity against peptide substrates, some iso-
zymes have both trypsin- and chymotrypsin-like activi-
ties, and some act in elastase-like function. Investigations
of the enzymes are focused on cardiovascular system for a
long time in this lab [24,25]. We found that the proteases
can activate not only prothrombin but also plasminogen.
However, whether the earthworm E. fetida synthesizes a
protease to degrade FN rapidly has been still unknown.
In this study, we show a novel protease from E. fetida,
which cleaves FN much more quickly than the other
serum proteins in vitro and in vivo. Sequentially, the cleav-
age sites on FN by EFNase and the effect on the produc-
tion of HBV antigens are also exhibited.
Methods
Materials
Human serum was got from health volunteers. FN (from
human plasma, the homogeneity is evaluated by immu-
noelectrophoresis) and fibronectin antibody (developed
in rabbit affinity isolated) were from Sigma-Aldrich
(USA). Peroxidase-conjugated IgG was from Beijing
Zhongshan Golden Bridge Biotechnology Co., LTD
(China). Lamivudine was the product from Beijing Nord-
huns Chemical Technology Co., LTD (China) and its
purity was higher than 99% measured by HPLC. Sprague-
Dawley (SD) rats were obtained from Vitalriver (China).
The animal experiments adhered to the principles of care
and use of laboratory animals and were approved by the
Institutional Animal Care and Use Committee of Peking
University Health Science Center.BMC Biochemistry 2008, 9:30 http://www.biomedcentral.com/1471-2091/9/30
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Cell culture
HepG2.2.15 cells were kindly provided by Dr Ding in the
Beijing Institute of Radiation Medicine who got them
from the Mount Sinai Medical Center in New York. Media
for HepG2.2.15 cell culture consisted of Dulbecco's mod-
ified eagle medium (high glucose, Gibco, Invitrogen Cor-
poration, USA) supplemented with 10% fetal bovine
serum (PAA, Austria), antibiotic G-418 sulfate (final con-
centration 380 μg/ml, Amresco, USA) and penicillin-
streptomycin solution (final concentrations 100 units/ml
penicillin and 100 μg/ml streptomycin, HyClone, USA).
Purification of EFNase
EFNase was purified by affinity chromatography as
described [26]. Briefly, crude earthworm proteases were
obtained from the ammonium sulfate precipitation of the
soluble proteins of earthworm E. fetida. EFNase was puri-
fied on a 4-aminobenzamidine dihydrochloride-coupled
Sepharose CL-6B affinity column (Pharmacia, USA)
eluted with a gradient of denaturant from 0.1 to 1 M
(AKTA prime plus, GE healthcare, Bio-science, USA).
Eight amino acid residues of the N-terminus were
sequenced (Applied Biosystem Automated Protein
Sequencer, Applied Biosystem Inc., USA).
Human serum fibronectin digested by EFNase
Human serum (25 μl) was incubated with different con-
centrations of EFNase (0, 0.4, 0.8, 1.6, 3.2, 6.4 and 10 μM)
at 37°C. After 30 min incubation, aliquots were taken and
diluted (10 times) immediately. The reaction was termi-
nated by addition of 2 × sample buffer and boiling for 10
min. Samples (18 μl each) were electrophoresed on 8%
SDS-PAGE. The protein bands in the gel were visualized
with Coomassie Brilliant Blue R-250. Then, under the
same conditions, the serum degradation in the presence
of EFNase (final concentration 6.4 μM) was observed at
different time intervals. Serum in the absence of EFNase
and in the presence of trypsin (final concentration 6.4
μM) was used as negative and positive controls, respec-
tively.
Identification of 'fibronectin' in the serum using mass 
spectrometry
The quick-diminished protein band 'fibronectin' was
digested by trypsin and subjected to MALDI-TOF MS [27].
The protein band of interest was excised from the gel and
cut into small pieces. Another piece from a protein-free
region of the gel was used as a parallel control for the
digestion to identify trypsin autoproteolysis products. 25
mM NH4HCO3 in 50% acetonitrile was added to wash the
gel particles and the gel particles dried in a vacuum centri-
fuge. 10 mM dithiothreitol in 25 mM NH4HCO3 was
added, enough to cover the gel pieces and reduce at 56°C
for 1 hr. Cooled to room temperature, the dithiothreitol
solution was replaced roughly by the same volume 55
mM iodoacetamide in 25 mM NH4HCO3. Samples were
incubated at room temperature in the dark with occa-
sional vortexing for 45 min. The gel pieces were washed
with 25 mM NH4HCO3 for 10 min while vortexing. They
were dehydrated with 25 mM NH4HCO3 in 50% ace-
tonitrile and rehydrated with 25 mM NH4HCO3  and
dehydrated again. The liquid phase was removed and the
gel pieces dried in a vacuum centrifuge. The gel particles
were rehydrated in 25 mM NH4HCO3 (pH 8) containing
0.05–0.1 mg/ml trypsin by vortexing for 5 min. After incu-
bated at 37°C for 12–16 h, the peptides were recovered
from the gel particles and used for MALDI-TOF MS analy-
sis (AXIMA-CFRTMPlus, Shimadzu, Japan). The peptide
fingerprint was processed in the NCBI database using the
MASCOT search program.
Proof of the band 'fibronectin' by western blotting
Western blotting was performed to prove the character of
the protein 'fibronectin' [28]. Different concentrations of
EFNase were incubated with human serum at 37°C for 2
h or EFNase (final concentration 6.4 μM) was incubated
with human serum at 37°C for different time intervals.
Aliquots were taken for 8% SDS-PAGE. The proteins in the
gel were electrotransferred onto nitrocellulose membrane
(Millipore, USA). The membrane was blocked in phos-
phate buffer solution (PBS) containing 5.0% nonfat milk
and then incubated with primary fibronectin antibody at
37°C for 2 h. After rinsing with PBS plus 0.2% Tween 20
(PBST), the membrane was subsequently exposed to the
second antibody peroxidase-conjuated IgG in the same
solution at 37°C for 2 h. Immunoreactive proteins were
visualized by 3,3'-diaminobenzidine (DAB) staining,
which generated a brown-colored product.
Fibronectin concentration change after oral 
administration of EFNase
Six male rats (SD, weighing 200–250 g) were fasted over-
night. Before oral administration of EFNase, blood sam-
ples were drawn from the ocular vein into tubes. Then
EFNase was given by gavage. Blood samples were drawn at
different time intervals (0.5, 1, 1.5, 2, 3, 4, 6, 8, and 26 h).
Sera were prepared and stored at -20°C until determina-
tion. Western blotting of the sera was conducted as men-
tioned above to test the change of FN. The concentrations
of FN in sera were determined by ELISA as described by
Özkan et al [29-31] with some modification. Sera samples
were diluted 1:50 and 50 μl aliquots were deposited on 96
well microtitration plates (Costar, USA). The plates were
incubated at 37°C for 2 h followed by five washing with
PBST buffer. Then the plates were blocked with 5% horse
serum in PBS at 37°C for 2 h. The primary fibronectin
antibody (diluted with PBS plus 5% horse serum at a ratio
of 1:10,000) was added 50μl per well and the plates were
incubated at 37°C for 2 h. The plates were then washed
five times with PBST. Peroxidase-conjuated Ig G (dilutedBMC Biochemistry 2008, 9:30 http://www.biomedcentral.com/1471-2091/9/30
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with PBS at a ratio 1:5000) was added 100 μl per well and
the plates were incubated at 37°C for 2 h. After the plates
were washed five times with PBST, substrate solution
(3,3',5,5'-tetramethylbenzidine, TMB) 100 μl were dis-
pensed per well with a multichannel pipet. The reaction
was stopped by adding 50 μl/well 2.0 M sulfuric acid.
After sufficient color development, absorbance values
were determined with an ELISA reader at a wavelength of
450 nm immediately.
Enzymolysis sites on fibronectin by EFNase
To investigate enzymolysis characteristics of EFNase, FN
from human plasma was used. First, FN (1 mg/ml, 10 μl)
incubated with EFNase at different final concentrations
(0, 0.01, 0.03, 0.1, 0.3, and 3 μM, respectively) at 37°C for
15 min to determine the suitable concentration of EFNase
to cleave FN. Then the proper concentration of EFNase
(final concentration 0.3 μM) was incubated with FN for 1,
5, 10, 30 and 60 min, respectively. The cleaved products
were electrophoresed on 8% reduced and non-reduced
SDS-PAGE and electrotransferred onto polyvinylidene
difluoride membrane (PVDF, Millipore, USA). After stain-
ing with Commassie Brilliant Blue R-250, the main
digested fragments were cut out for amino acid sequenc-
ing to identify the main cleavage sites.
Treatment of HepG2.2.15 cells by EFNase and lamivudine
HepG2.2.15 cells were seeded 1 × 104 cells per well in 96-
well cell culture plates [16]. EFNase and lamivudine (an
anti-HBV drug which is widely used in the therapy of
chronic hepatitis B) were added to the media 3 days after
seeding. Cells were grown in the presence of EFNase or
lamivudine for 6 days with changes of medium every 3
days. Six days after treatment by EFNase or lamivudine.
The culture supernatants were collected and subjected to
HBsAg and HBeAg analysis.
Assays of hepatitis B surface antigen and hepatitis B e 
antigen
Hepatitis B surface antigen (HBsAg) and hepatitis B e anti-
gen (HBeAg) in culture media were determined using
diagnostic kits for HBsAg and for HBeAg as described in
the manufacturer's manual (Sino-American Biotechnol-
ogy Co., China). The inhibition rates were calculated
according to the following formula: inhibition rate (%) =
(Acontrol - Atest)/Acontrol × 100% [16].
Cell viability assay
A colorimetric assay using CCK-8 was to assess cell viabil-
ity [32]. After the cells in 96-well plates were treated with
EFNase or lamivudine, the media were aspirated, and 10
μl of CCK-8 (Dojindo Labs, Japan) was added to each well
and incubated at 37°C for 1 h. The absorbance at 450 nm
that stands for cell growth was measured with the refer-
ence wavelength at 595 nm.
Results
Degradation of fibronectin in the presence of earthworm 
fibronectinase
The earthworm protease purified by ammonia sulfate pre-
cipitation followed by ionic and affinity chromatography
columns showed a single band on SDS-PAGE with an
apparent molecular mass of ~34 kDa (Figure 1). The N-
terminal region was sequenced and the first eight amino
acid residues were IVGGIEAR. The assay in the presence of
Chromozym Try (a trypsin substrate) showed the specific
activity of this protease was 176 units. One enzymic unit
is defined as one mg of enzyme causing conversion of 1
μM of substrate per minute at 25°C.
Purification of EFNase Figure 1
Purification of EFNase. SDS-PAGE of EFNase purified 
from Eisenia fetida. Lane 1 is the protein molecule markers; 
lane 2 represents EFNase.
97,400
66,200
43,000
31,000
20,100
lane 1 2
EFNase - +
Mol marker + -BMC Biochemistry 2008, 9:30 http://www.biomedcentral.com/1471-2091/9/30
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SDS-PAGE of the human serum treated by different pro-
tease concentration was showed in Additional file 1A.
Observably, a band of ~250 kDa protein in serum was
rapidly degraded (at 37°C in 15 min) in the presence of
the protease (final concentration 6.4 μM) (Figure 2A).
Serum in the absence of the protease was used as a nega-
tive control, showing little changes in the protein bands in
serum (Figure 2B). Trypsin (final concentration 6.4 μM)
used as a positive control (Additional file 1B) depicted a
relatively low hydrolytic activity on the ~250 kDa protein
by the densitomitric scanning analysis (Figure 2C). This
suggests that the earthworm protease has a significant
high enzymic activity on the ~250 kDa protein.
Now, the ~250 kDa protein should be identified. Mass
spectrometry was first employed (Additional file 2). Anal-
ysis on MALDI-TOF MS showed a peptide fingerprint of
'fibronectin' with degradation by trypsin. The database
searching results indicated that the protein was 'fibronec-
tin' with a molecular mass of ~252,842 Da. Among 31
peptides, 21 matched to the theoretical protonated molec-
ular masses of FN tryptic fragments within 50 ppm (Addi-
tional file 3). The sequences of the matched peptides
(match to Q60FE4 human, FN1, Homo sapiens) were
showed in Figure 3.
To further prove the band of 'fibronectin', western blot-
ting was employed. The fibronectin antibody was able to
recognize the serum protein well. When different concen-
trations of the earthworm protease (from 0.4 to 10 μM)
were incubated with human serum at 37°C for 2 h (Figure
4A), the ~250 kDa serum protein was rapidly degraded.
Furthermore, in the presence of the protease (6.4 μM,
37°C), the serum protein was markedly digested in 5 min
(Figure 4B). The digestion also showed concentration-
and time-dependent character.
Sequentially, the effect of EFNase on FN in vivo should be
investigated. As shown in Figure 5A, a typical western blot
pictured the degradation of FN in the rat serum after oral
administration of EFNase. The gray density of FN band
was descent and then ascent. The relative content of serum
FN significantly decreased from 1 to 4 h. ELISA results
showed that the mean lowest FN concentration in blood
occurred at ~4 h (Figure 5B). Therefore, the serum protein
is fibronectin (FN) and thus the protease is called earth-
worm fibronectinase (EFNase).
Cleavage sites on fibronectin
The digested FN fragments released from the incubation
with EFNase were shown in Figure 6. Human plasma
fibronectin existed mainly as 250 kDa monomer on the
reduced SDS-PAGE (Additional file 4A, lane 6). As the
enzyme concentration increased, the ~250 kDa monomer
was degraded, resulting in some smaller polypeptides
(Additional file 4A, lanes 1–5) and exhibiting a concentra-
tion-dependent character. Almost none of intact FN
remained when EFNase concentration was 3 μM. Thus,
0.3 μM of EFNase was employed to carry out the time-
dependent experiment (Figure 6A). On the gel, FN mono-
mer disappeared within 1 min followed by appearance of
digested bands. On reducing (Figure 6A) and Non-reduc-
ing (Figure 6B) SDS-PAGE, over ten digested fragments
appeared. With reference to the complete primary struc-
ture of human FN (NP002017, GenBank, mature peptide
part), four cleavage sites were determined (Table 1). Seven
fragments (bands 1, 2, 3, 4, 5, 9 and 10) cleaved at R259/
A260 (I), two (bands 6 and 12) at K1557/T1558 (III), one
(band 7) at R2039/H2040 (IV) and one (band 11) at R1005/
G1006 (II) were exhibited. Band 8 represented an N-termi-
nal region fragment.
The schematic diagram of the modular structure of FN
monomer is showed in Figure 7. The four cleavage sites
are also indicated on the diagram. From N-terminal to C-
terminal, the first cleavage site on FN is R259/A260(I).
This domain contains the N-terminal region that is
involved in crosslinking to coagulation factor XIIIa. Five
Type I repeats are also in this region, which is bound to
fibrin, heparin and bacteria. From Figure 6A, bands 1, 2
and 8 appear quickly, showing the sensitive site of R259/
A260 to EFNase. According to the N-terminal amino acid
sequence (QAQQMVQPQ) and the apparent molecular
mass (about 30 kDa), we deduced band 8 is the fragment
from Q1 to R259. The second cleavage site is at R1005/
G1006 (II). The collagen and gelation binding domain is
reported to localize between R259/A260 and R1005/
G1006 [1]. The third cleavage site is at K1557/T1558(III).
The important integrin-recognition motif RGD (in repeat
III10) is located in this part. The strongest heparin-bind-
ing site is between the third and the fourth cleavage site. A
binding site for HBsAg is from the variable sequence (V)
to C-terminus [33]. The fourth cleavage site (R2039/
H2040) is located at this region.
The main cleavage sites were at R and K, indicating a
trypsin alkaline serine-like protease of EFNase. BSA was
used as a control for the degradation, but the EFNase (0.3
μM) depicted a little hydrolysis on BSA (Additional file
4B). This suggests again that EFNase has a relatively high
specificity to FN.
HBsAg and HBeAg assays after the cells treated by EFNase 
and lamivudine
Because fibronectinolysis may disturb the virus binding
activity to FN, EFNase was used to treat HepG2.2.15 cells
to test its potential function in HBV infection.
HepG2.2.15 cells were the clonal cells derived from
HepG2 cells, transfected with a plasmid containing HBV
DNA. The cells secreted not only all HBV proteins but alsoBMC Biochemistry 2008, 9:30 http://www.biomedcentral.com/1471-2091/9/30
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Digestion of human serum in the presence of EFNase Figure 2
Digestion of human serum in the presence of EFNase. EFNase (final concentrations as indicated) was incubated with 
human serum (25 μl) at different time intervals during the degradation and then aliquots were taken for SDS-PAGE (panel A). 
Under the same conditions, serum in the absence of EFNase was used as negative control (panel B). Panel C was the compari-
son of the hydrolytic activity of EFNase and trypsin by densitomitric scanning analysis of Figure 2A and Additional file 1B.
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hepatitis B virions, whilst they were remarkably down-reg-
ulated by lamivudine [34]. As shown in Figure 8A and 8B,
EFNase and lamivudine were observed to inhibit the
secretion of HBsAg and HBeAg in HepG2.2.15 cell culture
medium. The ELISA results indicated that the secretion of
HBeAg was decreased by EFNase much more obvious than
by lamivudine. However, the inhibition of HBsAg secre-
tion in the presence of EFNase was less than lamivudine
under the experimental conditions.
To assess the potential toxicity of EFNase and lamivudine
to HepG2.2.15 cells, the viability of treated cells was
examined. The results showed that cell viability had little
change when the concentration of EFNase was lower than
34 nM under the experimental conditions (Figure 8C).
Lamivudine had little impact on the cell growth when its
concentration reached 100 μM (Figure 8D).
Discussion
In this study, the earthworm FNase has been found to rec-
ognize the ~250 kDa protein from human serum and
The sequences of the matched peptides Figure 3
The sequences of the matched peptides. Match to fibronectin 1, Homo sapiens, Q60FE4, GenBank.
1 MLRGPGPGLL LLAVQCLGTA VPSTGASKSK RQAQQMVQPQ SPVAVSQSKP 
51 GCYDNGKHYQ INQQWERTYL GNALVCTCYG GSRGFNCESK PEAEETCF……
351 YGGNSNGEPC VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTS NYEQDQKYSF
401 CTDHTVLVQT RGGNSNGALC HFPFLYNNHN YTDCTSEGRR DNMKWCGT……
501 NGRGEWTCIA YSQLRDQCIV DDITYNVNDT FHKRHEEGHM LNCTCFGQGR 
551 GRWKCDPVDQ CQDSETGTFY QIGDSWEKYV HGVRYQCYCY GRGIGEWH……
651 VGRWKEATIP GHLNSYTIKG LKPGVVYEGQ LISIQQYGHQ EVTRFDFT……
801 LILSTSQTTA PDAPPDPTVD QVDDTSIVVR WSRPQAPITG YRIVYSPS……
901 TPRSDTVPSP RDLQFVEVTD VKVTIMWTPP ESAVTGYRVD VIPVNLPGEH
951 GQRLPISRNT FAEVTGLSPG VTYYFKVFAV SHGRESKPLT AQQTTKLD……
1251 KDDKESVPIS DTIIPAVPPP TDLRFTNIGP DTMRVTWAPP PSIDLTNFLV
1301 RYSPVKNEED VAELSISPSD NAVVLTNLLP GTEYVVSVSS VYEQHEST……
1451 PRDLEVVAAT PTSLLISWDA PAVTVRYYRI TYGETGGNSP VQEFTVPGSK 
1501 STATISGLKP GVDYTITVYA VTGRGDSPAS SKPISINYRT EIDKPSQMQV 
1551 TDVQDNSISV KWLPSSSPVT GYRVTTTPKN GPGPTKTKTA GPDQTEMTIE 
1601 GLQPTVEYVV SVYAQNPSGE SQPLVQTAVT TIPAPTDLKF TQVTPTSLSA
1651 QWTPPNVQLT GYRVRVTPKE KTGPMKEINL APDSSSVVVS GLMVATKY……
1751 ITGFQVDAVP ANGQTPIQRT IKPDVRSYTI TGLQPGTDYK IYLYTLNDNA
1801 RSSPVVIDAS TAIDAPSNLR FLATTPNSLL VSWQPPRARI TGYIIKYEKP
1851 GSPPREVVPR PRPGVTEATI TGLEPGTEYT IYVIALKNNQ KSEPLIGR……
2101 ERMSESGFKL LCQCLGFGSG HFRCDSSRWC HDNGVNYKIG EKWDRQGENG 
2151 QMMSCTCLGN GKGEFKCDPH EATCYDDGKT YHVGEQWQKE YLGAICSCTC
2201 FGGQRGWRCD NCRRPGGEPS PEGTTGQSYN QYSQRYHQRT NTNVNCPIEC 
2251 FMPLDVQADR EDSRE
* All of the 21 digested peptides matches the fibronectin
(Red)BMC Biochemistry 2008, 9:30 http://www.biomedcentral.com/1471-2091/9/30
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The further proof of 'fibronectin' in serum by western blotting Figure 4
The further proof of 'fibronectin' in serum by western blotting. EFNase (final concentrations as indicated) was incu-
bated with human serum (25 μl) at 37°C for 120 min, and then aliquots were taken for SDS-PAGE and western blotting (panel 
A). EFNase was also added to serum and aliquots were taken for SDS-PAGE and western blotting at different time intervals 
during the degradation (panel B).
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digest it rapidly. We think that this serum protein is FN
because of the following results. (1) The molecular mass
of the protein is ~250 kDa, approximately equal to FN
(from 210 to 250 kDa). (2) The N-terminal amino acid
sequence is identical to that of FN (QAQQMVQPQ). (3)
The mass-spectrum shows a fingerprint of FN for the
trypsin digested serum protein. Finally, (4) EFNase
degrades the purified FN at the specific cleavage sites as
mentioned above.
It is necessary to explain why we call the earthworm pro-
tease as EFNase. First, we have known that R and K are the
main cleavage sites for the protease, exhibiting the trypsin
alkaline serine-like activity. 0.01 μM of the protease
digests FN within 15 min, showing a high hydrolytic activ-
ity to FN. Definitely, the protease is able to recognize FN
from a great number of proteins contained in human
Changes in fibronectin concentrations after EFNase oral administrated to rats Figure 5
Changes in fibronectin concentrations after EFNase oral administrated to rats. EFNase was oral administrated to 
rats at a dose 2000 mg/kg. Panel A was a typical western blotting picture of the serum. Lane 1 showed the serum before oral 
administration of EFNase as control; Lanes 2 through 9 were serum after oral administration of EFNase at time as indicated. 
Panel B was the FN concentrations determined by ELISA (Mean ± SD, n = 6). * P < 0.05, **P < 0.01 versus the FN concentration 
before oral administration of EFNase.
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Table 1: Cleavage sites on fibronectin by EFNase
Fragment No. cleavage site Cleavage site
1,2,3,4,5,9,10 I R259/A260
6,12 III K1557/T1558
7I V R 2039/H2040
8f r o m  Q 1 to R259
11 II R1005/G1006
The amino acid sequence of FN is referred to fibronectin 1 isoform 3 
preproprotein [NP002017, GenBank, mature peptide part].BMC Biochemistry 2008, 9:30 http://www.biomedcentral.com/1471-2091/9/30
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Digestion of fibronectin by EFNase Figure 6
Digestion of fibronectin by EFNase. EFNase (final concentrations as indicated) was incubated with FN at 37°C and aliq-
uots were taken at different time intervals for reducing SDS-PAGE during the degradation (panel A). Under the same condi-
tions, FN in the presence of EFNase was analyzed by non-reducing SDS-PAGE, compared with reducing SDS-PAGE. Lanes 2 
through 7 were non-reducing SDS-PAGE and lanes 8 to 9 were reducing SDS-PAGE (panel B).
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serum. Under the same conditions, trypsin as a control
did not rapidly degrade the serum FN. The earthworm
protease did not quickly digest BSA and the other serum
proteins. By in vivo experiments we have demonstrated
that the relative concentration of the serum FN will
decrease when the earthworm protease are orally admin-
istrated to rats. These results have given us an enlighten-
ment to consider the protease as an FNase.
As shown in the previous studies, the earthworm E. fetida
contains 8 trypsin-like proteases and their molecular
masses are around 30 kDa [35]. The apparent molecular
mass of the earthworm FNase is ~34 kDa (Figure 1), sim-
ilar to these proteases. The N-terminal sequence (8 amino
acid residues) of EFNase showed identical to that of one
isozymes of the earthworm protease (EfP-III-2, a trypsin-
like protease). However, the complete gene and the intact
amino acid sequence of EFNase have not been clarified.
Whether EFNase is EfP-III-2 remains further investigated.
To study the cleavage site of EFNase on FN, we have
employed plasma FN as the substrate. Although plasma
FN is distinct from cellular FN in some functions [36,37],
most of the amino acid sequence is similar between
plasma FN and cellular FN except EDA, EDB and V
regions. Plasma FN is much more soluble than the tissue
FN. Thus, it is convenient for us to analyze the degraded
fragments of plasma FN in the presence of EFNase. From
the results of plasma FN, we could predict some changes
of cellular FN in the presence of the earthworm proteases.
In fact, our unpublished data show that the concentration
of cellular FN in the HBV transgenic mice livers is indeed
decreased.
One of the important functions of FN is virus-binding
activity. A high concentration of FN in blood improves the
transmission frequency of hepatitis viruses [38]. Several
domains have been reported to participate in the viruses
binding to FN (see Figure 7). Liu and co-workers [4] have
shown that FN2 (with a sequence from N-terminus to
Type III3) mediates IHNV attachment and cell entry. HIV-
1IIIB specifically interacts with the III1-C region within FN
and the interaction may play a role in facilitating HIV
infection in vivo [11]. The C-terminal 120–140 kDa frag-
ment that carries the cell-binding activity bound influenza
A (H3N2, Bangkok strain) virus most efficiently [39]. A
binding site for HBsAg has been found in heparin binding
region II, and between the variable sequence (V) and C-
terminus [33]. This virus-binding ability may explain the
high rate of transmission of virus infections by plasma
derivates enriched in FN [38]. In this study, we hypothe-
sized that the cleavage of FN by EFNase may have the pos-
The main function domain of fibronectin digested by EFNase Figure 7
The main function domain of fibronectin digested by EFNase. The functional domains of FN digested by EFNase were 
shown in this panel. Ligands interaction regions and cleavage sites are shown (discussed in text). Variably spliced extradomain 
A (A) and extradomain B (B) modules and variable sequence (V) are shown in the subunit of the FN dimer.
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sibility to influence the binding activity of viruses to FN
and virus infections. However, the FN fragments may
elicit quite different function from the intact molecule
[40]. The cleavage products increase or decrease the bind-
ing effect needs further investigation.
For the cytological experiments, HBsAg and HBeAg
secreted by HepG2.2.15 cells were both inhibited when
the cells were treated with EFNase, especially the HBeAg
decreases more obviously. HBeAg has the best correlation
to the presence of infectious HBV. It is an important
marker of the infection. Once HBeAg seroconversion
takes place, there may be transition to the nonreplicative
phase, characterized by normal serum liver enzymes and
low HBV DNA levels and reduced hepatic necroinflamma-
tion [41]. The significant clearance of HBeAg by EFNase
may endow EFNase a potential product to treat HBV infec-
tion diseases.
The mechanism for EFNase to decrease HBeAg level in the
HepG2.2.15 cell culture is due to two possibilities. (1) The
cleavage of FN by EFNase may disturb the virus-binding
activity and may inhibit the initial steps of the virus entry
into target cells. (2) EFNase degrades HBeAg directly to
decrease the level of the antigen in the medium. But, this
possibility should not exist because HBsAg would be
digested if the EFNase substrate specificity was so broad
that all the proteins in the medium should be destroyed.
In general, the mechanism for EFNase to decreases HBeAg
remains further to be studied.
We have tried to find a drug with the same mechanism as
a positive control to the inhibition of the antigens pre-
duced by HepG2.2.15 cells. But no drug with such a char-
acteristic was found. Lamivudine is selected because it is
the first-line drug in treating chronic HBV infections on
clinic [20]. In research on HBV infections, lamivudine is
commonly used as a positive control. Meanwhile, lamivu-
dine, an oral antiviral agent, has the same administration
route with EFNase.
We adopted an oral administration route of the protease
to develop an oral administration dosage form. The FN
concentration in serum decreased when EFNase was orally
administrated to rats. As we know, earthworm proteases
have been formulated into the oral enteric-soluble cap-
sules which protect the enzymes from degradation in
stomach. This formulation whose efficiency is certified
has been successfully used on clinic for more than ten
years [21,22]. Furthermore, previous [42-44] and our
present (Additional file 5) investigations on the absorp-
Effect of EFNase on HBeAg and HBsAg secreted HepG2.2.15 cells and the cell viability Figure 8
Effect of EFNase on HBeAg and HBsAg secreted HepG2.2.15 cells and the cell viability. HBsAg and HBeAg in cell 
culture in the presence of EFNase (panel A) and lamivudine (panel B) were analyzed by ELISA. Cell viabilities treated with 
EFNase (panel C) and lamivudine (panel D) were determined using CCK-8 kits. The data represent means ± SD (n = 3).
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tion of the proteases indicate that the proteases could be
partially absorbed from intestines to blood.
As mentioned above, the enzyme has a high activity to
hydrolyze FN in serum. However, the protease could
hydrolyze some other proteins under the experimental
conditions (Figure 2). Furthermore, this protease is sup-
posed to digest some other proteins on the HepG 2.2.15
cells or in the serum of rats although we didn't detect the
degradation of the proteins.
An important cleavage site should be emphasized here is
R1005/G1006, which is involved in the binding of collagen
(Type I6–I9 and II1–II2). Cutting at this site may destroy
the interaction between FN and collagen. In fact, some
HBV infection evolves into liver cirrhosis and hepatocellu-
lar carcinoma. FN is important in the fibrogenesis. During
the early phase of active fibroplasia, FN production
increases dramatically, and this augmentation is associ-
ated with the fibroblast proliferation thereafter responsi-
ble for excessive synthesis and deposition of the collagen
protein. FN associated with collagen through the specific
binding sites, which promotes the formation of fibre. The
hydrolysis of FN by EFNase not only decreases FN concen-
tration directly, but also prevents the association of colla-
gen to FN, which probably delay the formation of fibre.
The current therapeutic agents (including interferon and
nucleoside analogues) used for the treatment of chronic
HBV are mainly prevent the replicate of the viruses. But
once the cirrhosis has occurred, it is difficult to be reversed
[45]. EFNase is supposed to be able to prevent both the
processes, which has some advantage over interferon and
nucleoside analogues. Thus we think that EFNase may
have the potential to be developed into a new medicine to
treat chronic HBV, liver cirrhosis and hepatocellular carci-
noma patients.
Conclusion
In conclusion, a novel EFNase that cleaved FN much faster
than the other proteins in mammal serum was purified
from E. fetida. The results suggest that EFNase may have
the potential to inhibit HBV infection through its sup-
pressing the level of FN and HBeAg.
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